SenesTech (SNES) Releases Earnings Results, Meets Estimates
SenesTech (NASDAQ:SNES) issued its earnings results on Wednesday. The company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10), Morningstar.com reports. SenesTech had a negative net margin of 4,009.43% and a negative return on equity of 182.12%.
Shares of NASDAQ:SNES opened at $1.68 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.74 and a quick ratio of 4.65. SenesTech has a fifty-two week low of $0.30 and a fifty-two week high of $2.37. The firm has a market cap of $39.33 million, a P/E ratio of -2.67 and a beta of 1.67.
A number of institutional investors have recently added to or reduced their stakes in the stock. Meitav Dash Investments Ltd. purchased a new stake in SenesTech during the first quarter valued at $81,000. Virtu Financial LLC raised its stake in SenesTech by 87.4% during the first quarter. Virtu Financial LLC now owns 56,447 shares of the company’s stock valued at $69,000 after purchasing an additional 26,322 shares in the last quarter. Finally, Vanguard Group Inc raised its stake in SenesTech by 35.3% during the third quarter. Vanguard Group Inc now owns 162,808 shares of the company’s stock valued at $112,000 after purchasing an additional 42,500 shares in the last quarter. 8.42% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “SenesTech (SNES) Releases Earnings Results, Meets Estimates” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/05/16/senestech-snes-releases-earnings-results-meets-estimates.html.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Read More: What is a put option?
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.